Impact of body mass index and obesity on clinical outcomes in the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ensure-af) randomized trial

In the ENSURE-AF study (NCT 02072434), the direct oral factor Xa inhibitor edoxaban (edox) showed similar efficacy and safety vs enoxaparin-warfarin (enox-warf) in patients (pts) undergoing electrical cardioversion of nonvalvular atrial fibrillation.This ancillary analysis compared the primary